Navigation Links
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on Their Investment in AMAG Pharmaceuticals, Inc. of Class Action Lawsuit Investigation - AMAG
Date:5/28/2013

NEW YORK, May 28, 2013 /PRNewswire/ -- Pomerantz Grossman Hufford Dahlstrom & Gross LLP is investigating claims on behalf of investors of AMAG Pharmaceuticals, Inc. ("AMAG" or the "Company") (NASDAQ: AMAG) (CUSIP: 00163U106 ) who purchased AMAG common stock between May 10, 2012 and May 21, 2013 (the "Class Period"). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 237.

The investigation concerns whether AMAG and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

On May 22, 2013, the Company announced in regulatory filing that it has been made aware by Takeda Pharmaceutical Company Limited, the exclusive product distributor of ferumoxytol in Switzerland, that it is recalling one specific batch of Rienso, ferumoxytol, from the Swiss market. This decision is based on a cluster of four post-marketing adverse event reports in Switzerland concerning hypersensitivity reactions of varying severity following the administration of Rienso from the recalled batch, and at least one fatality has occurred as a result of the use of the drug in Switzerland.  On this news announcement, shares of AMAG fell $2.68 or 10.68% to close at $22.40 on May 22, 2013.

The Pomerantz Firm, with offices in New York, Chicago, San Diego, and Florida, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz , known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 70 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

CONTACT:
Robert S. Willoughby
Pomerantz Grossman Hufford Dahlstrom & Gross LLP
rswilloughby@pomlaw.com


'/>"/>
SOURCE Pomerantz Grossman Hufford Dahlstrom & Gross LLP
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. OncoSec Medical Issues Letter to Shareholders
2. Faruqi & Faruqi, LLP is Investigating Pain Therapeutics Inc. on Behalf of its Shareholders (PTIE)
3. Amylin Pharmaceuticals, Inc. Shareholder Alert: Bernstein Liebhard LLP Announces Investigation Of Acquisition By Bristol-Myers Squibb Company
4. Ampios CEO and CSO Send Message to Shareholders
5. Berger & Montague, P.C. Reminds Viropharma Shareholders That The Deadline To Petition The Court To Act As Lead Plaintiff Is July 23, 2012
6. Sinovac Schedules 2012 Annual Meeting of Shareholders
7. Par Pharmaceutical Companies, Inc. Shareholder Alert: Bernstein Liebhard LLP Announces Investigation Of Acquisition By TPG
8. Johnson & Johnson Provides Notice Of Proposed Settlement Of Shareholder Derivative Actions, Final Settlement Hearing, And Right To Appear
9. Carl Icahn Issues Open Letter to Shareholders of Forest Laboratories
10. AMRI Renews Shareholder Rights Plan
11. AspenBio Pharma to Provide Shareholders with Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... Jersey and OR AKIVA, Israel ... Regentis Biomaterials Ltd., a leader in the ... Series D investment round on February 5, 2016. The ... Group ("Haisco"), a leading Chinese pharmaceutical manufacturer, and ... SCP Vitalife Partners, Generali Financial Holdings and both the ...
(Date:2/10/2016)... Feb. 10, 2016  Silicon Biosystems Menarini Inc., ... that help uncover the biological complexities of disease ... a developer of innovative technologies for genomics research, ... aimed at enabling translational researchers to obtain high-quality ... hundred tumor and normal cells in an optimized ...
(Date:2/10/2016)... 2016 On Tuesday, February 9th, the ... with its Arthritis Advisory Committee to discuss ... & Johnson,s Remicade and most likely the ... U.S. The Biologics Prescribers Collaborative (BPC) along ... for Patient Access, American Association of Clinical ...
Breaking Medicine Technology:
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... company is unveiling its revolutionary new 2.0 version at the International Roofing Expo ... “put the power of the world's most advanced weather technology in the hands ...
(Date:2/10/2016)... Garland, TX (PRWEB) , ... February 10, 2016 ... ... the commencement of a master charity program created to assist the local community. ... closely with community leaders and nonprofit organizations in the area. Their goal is ...
(Date:2/10/2016)... ... , ... Ongoing news of the ravages of traumatic brain injury (TBI) among ... that takes a closer look at cases of TBI being managed by their members. ... among the aging population, and identifies the challenges associated with their care. , During ...
(Date:2/10/2016)... ... 2016 , ... Armune BioScience signed a definitive agreement with ... centers across the country. Launched in April of 2015, Apifiny is the only cancer ... Apifiny order volume exceeded 3,000 tests in 2015. Primary care physicians and urologists have ...
(Date:2/10/2016)... ... February 10, 2016 , ... The ... been awarded the prestigious Distinguished Emerald Club of the World award, as determined ... magazine, one of the most respected trade publications serving private clubs. , “We’d ...
Breaking Medicine News(10 mins):